Among pregnant and postpartum individuals with #OpioidUseDisorder, longer duration of medications for opioid use disorder was associated with lower 1-year risk of overdose or death after delivery.

Among pregnant and postpartum individuals with #OpioidUseDisorder, longer duration of medications for opioid use disorder was associated with lower 1-year risk of overdose or death after delivery.
Among Medicaid-enrolled youths with #OpioidUseDisorder, only 1 in 6 received medication for opioid use disorder and only 1 in 32 had 180 days or more of medication retention.
Among patients with #OpioidUseDisorder offered buprenorphine in the emergency department, declination was associated more with concerns about precipitated withdrawal, physical dependence, and housing barriers than with lower treatment readiness. ja.ma/4hKNeCl
Patients with #OpioidUseDisorder reported that in-person methadone dosing visits required substantial travel time and cost, while wait times, clinic hours, and transportation barriers further limited treatment access. ja.ma/4hKL3Pb
New study: telemedicine bridge clinics improved buprenorphine continuity, cut ED visits 18%, lowered Medicaid spending. Co-authored by CP3's Julie Donohue.
Among patients hospitalized with #OpioidUseDisorder in Philadelphia, dexmedetomidine use rose after medetomidine emerged in the illicit fentanyl supply, and nearly all such admissions involved the intensive care unit.
September 24th is Save A Life Day!! Be a hero and carry naloxone. Reach out to your local prevention team for more details.
#savealifeday #opioidawareness #opioidusedisorder #naloxonesaveslives #narcansaveslives
Suboxone is an FDA-approved medication that supports a broader, structured treatment program for opioid addiction.
It’s only available in hospitals and rehab centers.
#OpioidDetox #Rehab #OpioidUseDisorder
Learn More:
https://buenavistarecovery.com/blog/going-to-detox-or-rehab-while-on-suboxone/
Among patients receiving #Methadone for #OpioidUseDisorder, take-home dosing after completed induction was associated with lower mortality vs no take-home dosing, with the greatest benefit when started within 5 to 12 weeks or 13 to 24 weeks. ja.ma/4cswSfX